TY - JOUR
T1 - Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2
AU - Higashi, Atsuko Yoshioka
AU - Ikawa, Tomokatsu
AU - Muramatsu, Masamichi
AU - Economides, Aris N.
AU - Niwa, Akira
AU - Okuda, Tomohiko
AU - Murphy, Andrew J.
AU - Rojas, Jose
AU - Heike, Toshio
AU - Nakahata, Tatsutoshi
AU - Kawamoto, Hiroshi
AU - Kita, Toru
AU - Yanagita, Motoko
PY - 2009/5/1
Y1 - 2009/5/1
N2 - The CreERT2 for conditional gene inactivation has become increasingly used in reverse mouse genetics, which enables temporal regulation of Cre activity using a mutant estrogen binding domain (ERT2) to keep Cre inactive until the administration of tamoxifen. In this study, we present the severe toxicity of ubiquitously expressed CreERT2 in adult mice and embryos. The toxicity of Cre recombinase or CreERT2 in vitro or in vivo organisms are still less sufficiently recognized considering the common use of Cre/loxP system, though the toxicity might compromise the phenotypic analysis of the gene of interest. We analyzed two independent lines in which CreERT2 is knocked-in into the Rosa26 locus (R26CreERT2 mice), and both lines showed thymus atrophy, severe anemia, and illegitimate chromosomal rearrangement in hematopoietic cells after the administration of tamoxifen, and demonstrated complete recovery of hematological toxicity in adult mice. In the hematopoietic tissues in R26CreERT2 mice, reduced proliferation and increased apoptosis was observed after the administration of tamoxifen. Flow cytometric analysis revealed that CreERT2 toxicity affected several hematopoietic lineages, and that immature cells in these lineages tend to be more sensitive to the toxicity. In vitro culturing of hematopoietic cells from these mice further demonstrated the direct toxicity of CreERT2 on growth and differentiation of hematopoietic cells. We further demonstrated the cleavage of the putative cryptic/pseudo loxP site in the genome after the activation of CreERT2 in vivo. We discussed how to avoid the misinterpretation of the experimental results from potential toxic effects due to the activated CreERT2.
AB - The CreERT2 for conditional gene inactivation has become increasingly used in reverse mouse genetics, which enables temporal regulation of Cre activity using a mutant estrogen binding domain (ERT2) to keep Cre inactive until the administration of tamoxifen. In this study, we present the severe toxicity of ubiquitously expressed CreERT2 in adult mice and embryos. The toxicity of Cre recombinase or CreERT2 in vitro or in vivo organisms are still less sufficiently recognized considering the common use of Cre/loxP system, though the toxicity might compromise the phenotypic analysis of the gene of interest. We analyzed two independent lines in which CreERT2 is knocked-in into the Rosa26 locus (R26CreERT2 mice), and both lines showed thymus atrophy, severe anemia, and illegitimate chromosomal rearrangement in hematopoietic cells after the administration of tamoxifen, and demonstrated complete recovery of hematological toxicity in adult mice. In the hematopoietic tissues in R26CreERT2 mice, reduced proliferation and increased apoptosis was observed after the administration of tamoxifen. Flow cytometric analysis revealed that CreERT2 toxicity affected several hematopoietic lineages, and that immature cells in these lineages tend to be more sensitive to the toxicity. In vitro culturing of hematopoietic cells from these mice further demonstrated the direct toxicity of CreERT2 on growth and differentiation of hematopoietic cells. We further demonstrated the cleavage of the putative cryptic/pseudo loxP site in the genome after the activation of CreERT2 in vivo. We discussed how to avoid the misinterpretation of the experimental results from potential toxic effects due to the activated CreERT2.
UR - http://www.scopus.com/inward/record.url?scp=66949153645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66949153645&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.0802413
DO - 10.4049/jimmunol.0802413
M3 - Article
C2 - 19380810
AN - SCOPUS:66949153645
SN - 0022-1767
VL - 182
SP - 5633
EP - 5640
JO - Journal of Immunology
JF - Journal of Immunology
IS - 9
ER -